Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
- Conditions
- Gastric CancerGastroesophageal-junction CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Target Recruit Count
- 950
- Registration Number
- NCT06093425
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
- Conditions
- Locally Advanced Solid TumorMetastatic TumorColorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT05731271
- Locations
- 🇺🇸
OHSU, Portland, Oregon, United States
🇺🇸Mary Crowley, Dallas, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Locally Advanced or Metastatic CancersMetastatic Human Papillomavirus-Related Malignant Neoplasm
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04958434
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT04495296
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
- Conditions
- Advanced CancerGastric CancerGastroesophageal-junction CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Suzhou Transcenta Therapeutics Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04396821
- Locations
- 🇺🇸
Banner MD Anderson, Gilbert, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Yale University, New Haven, Connecticut, United States
- Prev
- 1
- 2
- Next